Katherine Stueland Sells 1,078 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 1,078 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $89.44, for a total value of $96,416.32. Following the transaction, the chief executive officer now directly owns 6,674 shares of the company’s stock, valued at approximately $596,922.56. This represents a 13.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Monday, March 17th, Katherine Stueland sold 10,559 shares of GeneDx stock. The shares were sold at an average price of $96.71, for a total value of $1,021,160.89.
• On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The shares were sold at an average price of $94.73, for a total value of $258,707.63.
• On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36.
• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total transaction of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The shares were sold at an average price of $78.18, for a total transaction of $1,407,709.08.

GeneDx Price Performance

WGS stock opened at $94.46 on Tuesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company’s 50-day moving average is $84.69 and its 200-day moving average is $70.37. The stock has a market capitalization of $2.65 billion, a PE ratio of -48.19 and a beta of 1.91. GeneDx Holdings Corp. has a 1 year low of $7.72 and a 1 year high of $115.60.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The business had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. Equities research analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on WGS shares. The Goldman Sachs Group boosted their price objective on GeneDx from $70.00 to $80.00 and gave the company a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen lifted their target price on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $72.33.

Institutional Trading of GeneDx

Several hedge funds have recently bought and sold shares of WGS. Vanguard Group Inc. raised its holdings in GeneDx by 18.5% during the fourth quarter. Vanguard Group Inc. now owns 1,006,210 shares of the company’s stock worth $77,337,000 after buying an additional 156,768 shares during the last quarter. Summit Partners Public Asset Management LLC raised its holdings in shares of GeneDx by 336.9% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 755,564 shares of the company’s stock worth $58,073,000 after acquiring an additional 582,619 shares during the last quarter. William Blair Investment Management LLC acquired a new stake in shares of GeneDx in the 4th quarter worth about $51,496,000. Lord Abbett & CO. LLC bought a new position in GeneDx in the 4th quarter valued at about $48,458,000. Finally, Fred Alger Management LLC boosted its stake in GeneDx by 38.5% during the 4th quarter. Fred Alger Management LLC now owns 546,054 shares of the company’s stock valued at $41,970,000 after purchasing an additional 151,824 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.